Annexin Pharmaceuticals AB (publ) (ANNX.ST)
SEK 0.3
(14.23%)
SEK 0.3
(14.23%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -43.86 Million SEK | -7.67% |
| 2022 | -40.53 Million SEK | 19.01% |
| 2021 | -50.09 Million SEK | -14.97% |
| 2020 | -43.54 Million SEK | -54.39% |
| 2019 | -28.13 Million SEK | 1.3% |
| 2018 | -28.5 Million SEK | 6.98% |
| 2017 | -30.37 Million SEK | -217.8% |
| 2016 | -9.7 Million SEK | -94.32% |
| 2015 | -4.97 Million SEK | -23790576.19% |
| 2014 | 115.59 Thousand SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -12.45 Million SEK | 14.41% |
| 2024 Q2 | -14.44 Million SEK | -16.02% |
| 2024 Q3 | -10.92 Million SEK | 24.1% |
| 2023 Q3 | -10.72 Million SEK | -27.02% |
| 2023 Q2 | -8.44 Million SEK | 16.43% |
| 2023 FY | - SEK | -7.67% |
| 2023 Q1 | -10.1 Million SEK | 0.19% |
| 2023 Q4 | -14.84 Million SEK | -38.45% |
| 2022 Q2 | -11.51 Million SEK | -21.86% |
| 2022 Q1 | -9.44 Million SEK | 27.84% |
| 2022 Q4 | -10.12 Million SEK | -4.95% |
| 2022 Q3 | -9.64 Million SEK | 16.23% |
| 2022 FY | - SEK | 19.01% |
| 2021 Q1 | -19.05 Million SEK | -16.39% |
| 2021 Q2 | -10.19 Million SEK | 46.49% |
| 2021 Q4 | -13.09 Million SEK | -60.1% |
| 2021 FY | - SEK | -14.97% |
| 2021 Q3 | -8.17 Million SEK | 19.81% |
| 2020 Q3 | -8.19 Million SEK | 29.28% |
| 2020 Q4 | -16.37 Million SEK | -99.76% |
| 2020 Q1 | -7.57 Million SEK | 26.82% |
| 2020 FY | - SEK | -54.39% |
| 2020 Q2 | -11.59 Million SEK | -52.98% |
| 2019 Q3 | -6.46 Million SEK | -8.1% |
| 2019 FY | - SEK | 1.3% |
| 2019 Q4 | -10.35 Million SEK | -60.2% |
| 2019 Q2 | -5.97 Million SEK | -7.98% |
| 2019 Q1 | -5.53 Million SEK | 23.75% |
| 2018 Q2 | -7.65 Million SEK | 14.73% |
| 2018 Q1 | -8.97 Million SEK | 5.89% |
| 2018 Q3 | -4.81 Million SEK | 37.01% |
| 2018 Q4 | -7.26 Million SEK | -50.65% |
| 2018 FY | - SEK | 6.98% |
| 2017 Q1 | -7.42 Million SEK | -110.13% |
| 2017 FY | - SEK | -217.8% |
| 2017 Q2 | -10.12 Million SEK | -36.44% |
| 2017 Q3 | -3.76 Million SEK | 62.83% |
| 2017 Q4 | -9.53 Million SEK | -153.23% |
| 2016 Q2 | -873 Thousand SEK | -42.18% |
| 2016 Q1 | -614 Thousand SEK | 0.0% |
| 2016 FY | - SEK | -94.32% |
| 2016 Q4 | -3.53 Million SEK | 25.82% |
| 2016 Q3 | -4.76 Million SEK | -445.59% |
| 2015 FY | - SEK | -23790576.19% |
| 2014 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 88.075% |
| Camurus AB (publ) | 562.54 Million SEK | 107.797% |
| Mendus AB (publ) | -97.84 Million SEK | 55.173% |
| Lipum AB (publ) | -37.11 Million SEK | -18.163% |
| NextCell Pharma AB | -40.98 Million SEK | -7.017% |
| Simris Alg AB (publ) | -22.36 Million SEK | -96.132% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -156.73% |
| Active Biotech AB (publ) | -43.88 Million SEK | 0.059% |
| Amniotics AB (publ) | -27.14 Million SEK | -61.592% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -208.511% |
| BioArctic AB (publ) | 275.38 Million SEK | 115.927% |
| Cantargia AB (publ) | -284.31 Million SEK | 84.573% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -124.021% |
| CombiGene AB (publ) | -35.33 Million SEK | -24.125% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 68.86% |
| Genovis AB (publ.) | 64.57 Million SEK | 167.926% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 61.829% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -18.466% |
| Intervacc AB (publ) | -68.98 Million SEK | 36.415% |
| Kancera AB (publ) | -61.88 Million SEK | 29.13% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -63.764% |
| LIDDS AB (publ) | -39.67 Million SEK | -10.565% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -262.368% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 239.667% |
| OncoZenge AB (publ) | 7.26 Million SEK | 703.647% |
| Saniona AB (publ) | -69.69 Million SEK | 37.067% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 86.184% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 84.448% |
| Xintela AB (publ) | -53.47 Million SEK | 17.972% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 74.171% |
| Ziccum AB (publ) | -20.34 Million SEK | -115.618% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 2193150.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 81.541% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -2008.702% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -226.565% |
| Corline Biomedical AB | -1.69 Million SEK | -2493.791% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 74.694% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 19.97% |
| Aptahem AB (publ) | -10 Million SEK | -338.206% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 479.782% |
| Fluicell AB (publ) | -25.91 Million SEK | -69.256% |
| Biovica International AB (publ) | -119.5 Million SEK | 63.298% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -3.877% |
| AcouSort AB (publ) | -16.7 Million SEK | -162.594% |
| Abliva AB (publ) | -93.6 Million SEK | 53.144% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 86.255% |
| 2cureX AB (publ) | -35.13 Million SEK | -24.832% |
| I-Tech AB | 30.34 Million SEK | 244.541% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 93.862% |
| Cyxone AB (publ) | -20.41 Million SEK | -114.857% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 57.189% |
| Biosergen AB | 228 Thousand SEK | 19337.281% |
| Nanologica AB (publ) | -62.11 Million SEK | 29.392% |
| SynAct Pharma AB | -222.7 Million SEK | 80.305% |
| BioInvent International AB (publ) | -312.7 Million SEK | 85.974% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 14275.552% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 104533.439% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 81.064% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -397.715% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 59.597% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -282.431% |